CBT005 / CanBas, Nihon University - LARVOL DELTA

CBT005Notice of receipt of allowance from the U.S. Patent Office [Google translation] (Nikkei) - "We are pleased to announce that we have received a patent allowance from the United States Patent and Trademark Office for CBT005, an immune system anti-cancer drug candidate compound we have developed....The acquisition of this new patent is the result of Canbas' accumulated knowledge in the field of immuno-oncology and experience in peptide drug development, and demonstrates the company's high drug discovery pipeline creation capabilities, which are the source of its corporate value. In the medium term, we plan to move CBT005 into preclinical trials and make it one of our promising development pipelines."

Patent • Preclinical • Pancreatic Cancer

Canvas moves forward with the development of next-generation anticancer drugs! Started research collaboration with Nihon University School of Medicine on CBT005 [Google translation] (Zaikei Shimbun) - "On the 14th, Canvas...began a research collaboration with Nihon University School of Medicine, Institute of Comprehensive Medicine (Itabashi-ku, Tokyo) regarding CBT005, a next-generation development pipeline candidate compound that the company is currently researching....The company regards this research collaboration as one of the preparations for advancing CBT005 to preclinical trials. First, we will begin contract research to comprehensively examine the antitumor effect by administering CBT005 and immune checkpoint blocking antibodies in combination to model mice* that naturally develop pancreatic cancer."

Licensing / partnership